Company profile

Verve Therapeutics

VERV · NASDAQ

Public Market Listing

VERVNASDAQ

NASDAQ primary exchange listing

Live quotes, historical charts, and market capitalization for Verve Therapeutics are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
VERVE-102
Phase 1
PCSK9 gene (hepatocyte genomic DNA)Gene therapy / editing
Atherosclerotic Cardiovascular Disease
VERVE-201
Phase 1
ANGPTL3 gene (hepatocyte genomic DNA)Gene therapy / editing
Atherosclerotic Cardiovascular Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.